BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9211757)

  • 1. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
    J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
    Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
    Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
    Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
    Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
    J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
    Verhoeff NP; Bemelman FJ; Wiersinga WM; van Royen EA
    Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of thyrotropin-secreting pituitary microadenoma with normal thyrotropin alpha-subunit level.
    Ozata M; Oztürk E; Narin Y; Tayfun C; Azal O; Beyhan Z; Corakçi A; Bayhan H; Gündoğan MA
    Thyroid; 1997 Jun; 7(3):441-7. PubMed ID: 9226217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
    Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
    Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
    Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.